Percheron Therapeutics Limited

OTCPK:PERC.F Stock Report

Market Cap: US$48.8m

Percheron Therapeutics Valuation

Is PERC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PERC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PERC.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PERC.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PERC.F?

Key metric: As PERC.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PERC.F. This is calculated by dividing PERC.F's market cap by their current revenue.
What is PERC.F's PS Ratio?
PS Ratio26.4x
SalesAU$2.97m
Market CapAU$75.26m

Price to Sales Ratio vs Peers

How does PERC.F's PS Ratio compare to its peers?

The above table shows the PS ratio for PERC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16.1x
IRD Opus Genetics
4x62.0%US$33.1m
SCYX SCYNEXIS
6.1x30.8%US$52.0m
IGC IGC Pharma
24.5x10.1%US$29.0m
NTRB Nutriband
29.8xn/aUS$53.8m
PERC.F Percheron Therapeutics
26.4x45.3%US$75.3m

Price-To-Sales vs Peers: PERC.F is expensive based on its Price-To-Sales Ratio (26.4x) compared to the peer average (16.1x).

Price to Sales Ratio vs Industry

How does PERC.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$4.12b
PRGO Perrigo
0.9x3.4%US$3.93b
BHC Bausch Health Companies
0.3x1.5%US$2.99b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.59b
PERC.F 26.4xIndustry Avg. 3.0xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PERC.F is expensive based on its Price-To-Sales Ratio (26.4x) compared to the US Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is PERC.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PERC.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PERC.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PERC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.14
0%
23.7%US$0.17US$0.093n/a3
Nov ’25n/a
US$0.14
0%
25.7%US$0.18US$0.093n/a3
Oct ’25n/a
US$0.15
0%
25.7%US$0.19US$0.097n/a3
Sep ’25n/a
US$0.15
0%
25.7%US$0.18US$0.095n/a3
Aug ’25n/a
US$0.14
0%
25.5%US$0.18US$0.094n/a3
Jul ’25n/a
US$0.17
0%
8.0%US$0.18US$0.15n/a2
Jun ’25US$0.012
US$0.17
+1,286.0%
8.0%US$0.18US$0.15n/a2
May ’25n/a
US$0.16
0%
8.0%US$0.18US$0.15n/a2
Apr ’25n/a
US$0.16
0%
8.0%US$0.18US$0.15n/a2
Mar ’25n/a
US$0.16
0%
8.0%US$0.18US$0.15n/a2
Feb ’25n/a
US$0.16
0%
8.0%US$0.18US$0.15n/a2
Jan ’25US$0.01
US$0.17
+1,581.1%
13.2%US$0.19US$0.15n/a2
Dec ’24n/a
US$0.17
0%
13.2%US$0.19US$0.15n/a2
Nov ’24n/a
US$0.17
0%
13.2%US$0.19US$0.15n/a2
Oct ’24n/a
US$0.17
0%
13.2%US$0.19US$0.15n/a2
Sep ’24n/a
US$0.17
0%
13.2%US$0.19US$0.15n/a2
Aug ’24n/a
US$0.19
0%
7.1%US$0.20US$0.17n/a2
Jul ’24n/a
US$0.21
0%
16.1%US$0.24US$0.17n/a2
Jun ’24n/a
US$0.21
0%
16.1%US$0.24US$0.17US$0.0122
May ’24US$0.055
US$0.22
+294.1%
16.1%US$0.25US$0.18n/a2
Apr ’24n/a
US$0.22
0%
16.1%US$0.25US$0.18n/a2
Mar ’24n/a
US$0.22
0%
16.1%US$0.25US$0.18n/a2
Feb ’24US$0.068
US$0.21
+214.6%
16.1%US$0.25US$0.18n/a2
Jan ’24n/a
US$0.21
0%
16.1%US$0.24US$0.18US$0.012
Dec ’23US$0.065
US$0.21
+221.1%
16.1%US$0.24US$0.18n/a2
Nov ’23n/a
US$0.21
0%
16.1%US$0.24US$0.18n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.57

7D

-3.2%

1Y

70.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.5%

1Y

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

-0.2%

1Y

-7.1%